Explore news and
events about us

Aurigene in the media

Look at how we are addressing global patient needs with novel cancer therapeutics

October 8, 2024

Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy...

Bengaluru & Hyderabad, India; October 8, 2024: Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a...

September 14, 2024

Indian Council of Medical Research Signs Memorandum of Agreements with Industry and Academic Partners to Advance First-in-Human Phase 1 Clinical...

A key milestone in the pursuit of affordable and accessible cutting-edge treatments for all citizens: Union Minister Shri J P...

July 5, 2022

Aurigene Discovery Technologies Limited Announces Drug Discovery, Development, and Commercialization Partnership with EQRx

BENGALURU, India--(BUSINESS WIRE)--The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx's pioneering business model to accelerate the development...

News

October 8, 2024

Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy...

Bengaluru & Hyderabad, India; October 8, 2024: Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a...

September 14, 2024

Indian Council of Medical Research Signs Memorandum of Agreements with Industry and Academic Partners to Advance First-in-Human Phase 1 Clinical...

A key milestone in the pursuit of affordable and accessible cutting-edge treatments for all citizens: Union Minister Shri J P...

July 5, 2022

Aurigene Discovery Technologies Limited Announces Drug Discovery, Development, and Commercialization Partnership with EQRx

BENGALURU, India--(BUSINESS WIRE)--The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx's pioneering business model to accelerate the development...

June 9, 2022

Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies

SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited...

December 14, 2021

Exelixis in-licenses second anti-cancer compound from Aurigene following FDA acceptance of investigational new drug application for phase 1 clinical trial...

– Robust preclinical data support Exelixis’ clinical development of XL114, with phase 1 trial in Non-Hodgkin’s lymphoma expected to begin...

February 19, 2020

Aurigene Announces First Patient Dosed with AUR101 in Phase II Study in Patients with Moderate to Severe Psoriasis

PRESS RELEASE Aurigene Announces First Patient Dosed with AUR101 in Phase II Study in Patients with Moderate to Severe Psoriasis...

Events

Keep abreast of our presence at biotech and drug discovery events

September 24, 2024

September 30- October 3, 2024, Discovery on Target

1) Discovery and Development of pan-KRAS Degraders for Cancer Therapyn 2) Efficacy of a First-in-Class Polymerase Theta Degrader in Preclinical...

September 1, 2024

September 1-5, 2024, XXVIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2024)

1) Distinctive Roles for Small Molecule Inhibitors of Immune Checkpoint Proteins (LE072)

Warning: Undefined variable $post in /storage/v2188/aurigene-com/public_html/wp-content/themes/aurigene_child/components/event_listing.php on line 14

Warning: Attempt to read property "ID" on null in /storage/v2188/aurigene-com/public_html/wp-content/themes/aurigene_child/components/event_listing.php on line 14

November 5, 2022